Latest Pharma and Biotech News
Biotechnology
10 December 2024 Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma.
Today's issue
Refine Search
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences . 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Pharmaceutical
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease. 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Biotechnology
Gilead Sciences has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting. 10 December 2024
Biotechnology
French biotechnology company MaaT Pharma remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD). 10 December 2024
Pharmaceutical
The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM; USA, France, Germany, Italy. Spain, the UK and Australia) is forecast to grow at a compound annual growth rate (CAGR) of 26.7% from $582 million in 2020 to $6.2 billion in 2030, with the pediatric and adult segments accounting for $2.2 billion and $4.0 billion, respectively, according to pharma analytics company GlobalData. 10 December 2024
Biotechnology
New data from Johnson & Johnson's Phase III CARTITUDE-4 study highlight the performance of Carvykti (ciltacabtagene autoleucel) in multiple myeloma. 10 December 2024
Pharmaceutical
South Korean biotech SK Biopharmaceuticals has unveiled the Phase III clinical trial results of Xcopri (cenobamate) in Northeast Asian epilepsy patients through a poster presentation at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, USA. 10 December 2024
Biotechnology
The BIOSECURE Act—US legislation aimed at safeguarding the country’s interests against potential security threats from China—is facing further delay. 10 December 2024
Pharmaceutical
Vivoryon Therapeutics has announced Phase II data from its VIVA-MIND study of varoglutamstat, an investigational oral glutaminyl cyclase inhibitor. 10 December 2024
Biotechnology
UK-based biotech Relation Therapeutics today announced two multi-program strategic collaborations with pharma major GSK . 10 December 2024
All news
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences . 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Pharmaceutical
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease. 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Biotechnology
Gilead Sciences has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting. 10 December 2024
Biotechnology
French biotechnology company MaaT Pharma remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD). 10 December 2024
Pharmaceutical
The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM; USA, France, Germany, Italy. Spain, the UK and Australia) is forecast to grow at a compound annual growth rate (CAGR) of 26.7% from $582 million in 2020 to $6.2 billion in 2030, with the pediatric and adult segments accounting for $2.2 billion and $4.0 billion, respectively, according to pharma analytics company GlobalData. 10 December 2024
Biotechnology
New data from Johnson & Johnson's Phase III CARTITUDE-4 study highlight the performance of Carvykti (ciltacabtagene autoleucel) in multiple myeloma. 10 December 2024
Pharmaceutical
South Korean biotech SK Biopharmaceuticals has unveiled the Phase III clinical trial results of Xcopri (cenobamate) in Northeast Asian epilepsy patients through a poster presentation at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles, USA. 10 December 2024
Biotechnology
The BIOSECURE Act—US legislation aimed at safeguarding the country’s interests against potential security threats from China—is facing further delay. 10 December 2024
Pharmaceutical
Vivoryon Therapeutics has announced Phase II data from its VIVA-MIND study of varoglutamstat, an investigational oral glutaminyl cyclase inhibitor. 10 December 2024
Biotechnology
UK-based biotech Relation Therapeutics today announced two multi-program strategic collaborations with pharma major GSK . 10 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze